<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822770</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0772</org_study_id>
    <nct_id>NCT00822770</nct_id>
  </id_info>
  <brief_title>Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin</brief_title>
  <official_title>G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the safety of AMD3100 (plerixafor)
      and G-CSF (filgrastim) in combination with fludarabine, busulfan, and an allogeneic blood
      stem cell transplant. This treatment will be studied in patients with acute myeloblastic
      leukemia (AML), myelodysplastic syndromes (MDS), or Chronic myelogenous leukemia (CML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Treatment:

      Fludarabine is a chemotherapy drug that is designed to make cancer cells less able to repair
      damaged DNA (the genetic material of cells). This may increase the likelihood of the cells
      dying.

      Busulfan is a chemotherapy drug that is designed to bind to DNA, which may cause cancer cells
      to die. It is commonly used in stem cell transplants.

      Plerixafor and filgrastim are designed to cause cancer cells to move from the bone marrow
      into the blood stream. This may help to make the cancer cells more sensitive to being killed
      by the chemotherapy.

      An &quot;allogeneic&quot; (from a donor) stem cell transplant is designed to help the recipient's body
      attack the cancer cells that may remain in the body after chemotherapy.

      Study Groups and Plerixafor Dose Levels:

      If you are found to be eligible to take part in this study, you will be assigned to a study
      group based on when you joined this study. Up to 4 groups of 3 participants will be enrolled
      in the Phase I portion of the study, and up to 48 participants will be enrolled in Phase II.

      If you are enrolled in the Phase I portion, the dose of plerixafor you receive will depend on
      when you joined this study. The first group of participants will receive the lowest dose
      level of plerixafor. Each new group will receive a higher dose of plerixafor than the group
      before it, if no intolerable side effects were seen. This will continue until the highest
      tolerable dose of plerixafor is found.

      If you are enrolled in Phase II, you will receive plerixafor at the highest dose that was
      tolerated in the Phase I portion.

      In this study, plerixafor is the only study drug where different dose levels are being tested
      and compared.

      Drug Administration Before the Transplant:

      You will receive your first dose of filgrastim on Day -9. (Day -9 means 9 days before the
      stem cell transplant, which will occur on Day 0).

      Filgrastim is injected under the skin once a day from Day -9 through Day -4. Plerixafor is
      injected under the skin once a day from Day -7 through Day -4. The plerixafor injections will
      occur 8 hours before the fludarabine and busulfan chemotherapy.

      The fludarabine and busulfan will be given by vein through a central venous catheter (CVC). A
      CVC is a sterile flexible tube that will be placed into a large vein while you are under
      local anesthesia. Your doctor will explain this procedure to you in more detail, and you will
      be required to sign a separate consent form for this procedure.

      Fludarabine is given once a day from Day -6 through Day -3, over 1 hour each time. On these
      same days, busulfan will be given after the fludarabine, over 3 hours.

      You will also receive tacrolimus in order to lower the risk of graft vs. host disease (GVHD).
      GVHD is a disease that occurs when the donor's immune cells react against the recipient's
      body, attacking the recipient's cells and tissues.

      Starting on Day -2, tacrolimus will be given as a continuous (non-stop) infusion through the
      CVC. When the study doctor decides it seems safe, you will begin taking tacrolimus by mouth
      instead, for as long as the study doctor decides is necessary.

      If your stem cell donor is not someone who is related to you, you will receive antithymocyte
      globulin (ATG) through the CVC once a day from Day -3 through Day -1. On Day -3, it will be
      given over at least 6 hours. On Days -2 and -1, it will be given over at least 4 hours. This
      drug is given in order to weaken your immune system in order to lower the risk of your immune
      system rejecting the transplanted cells.

      Blood Tests Before the Transplant:

      If you are in the Phase I part of this study, the following blood samples will be drawn and
      are not optional. Eight total blood samples (about 1 1/2 teaspoons each) will be drawn daily
      with your routine morning labs beginning before your first dose of study therapy (or Day -9)
      through Day -3. These samples will be used for research purposes, to study how the
      chemotherapy drugs and transplant may affect your normal cells and cancerous cells.

      If you are in the Phase II part of the study the following blood samples are optional and if
      you agree, eight total blood samples (about 1 1/2 teaspoons each) will be drawn daily
      beginning before your first dose of study therapy (or Day -9) through Day -3. These samples
      will be used for research purposes, to study how the chemotherapy drugs and transplant may
      affect your normal cells and cancerous cells.

      Stem Cell Transplant:

      On Day 0, after 2 days of rest from chemotherapy, the donor's stem cells will be given to you
      by vein (through the CVC). This should take about 30-60 minutes.

      Drug Administration After the Transplant:

      In addition to continuing to receive tacrolimus to lower the risk of GVHD (as described
      above), after the transplant you will also receive methotrexate to lower the risk of GVHD.
      Methotrexate will be given by vein, through the CVC, over 15 minutes on Days 1, 3, and 6. It
      will also be given on Day 11 if your stem cell donor is someone who is not related to you.

      Once a day, starting at 1 week after the transplant, you will receive filgrastim as an
      injection under your skin. These daily injections will continue until your blood counts
      recover.

      Reasons for Stopping the Study Treatment Early:

      If you experience intolerable side effects or the disease gets worse during study treatment,
      you will be taken off the study treatment.

      Other Procedures After the Transplant:

      You will remain in the hospital until your blood counts recover (usually about 4 weeks after
      the transplant). You will continue being monitored for any infections and transplant-related
      side effects for at least 100 days after the transplant.

      At 1, 3, 6, and 12 months after the transplant, you will have blood tests (about 3
      tablespoons) and bone marrow biopsies performed to check the status of the disease.

      Length of Study Participation:

      Your active participation in this study will be over at 12 months after the transplant. The
      study staff will continue to contact your local doctor regularly from then on. The purpose is
      to check the status of the disease and see how you are doing.

      Up to 72 patients will take part in this study. All will be enrolled at The University of
      Texas (UT) MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) Plerixafor</measure>
    <time_frame>28 day cycle (Plerixafor Day -7 to Day -4)</time_frame>
    <description>MTD dose of Plerixafor in combination with a fixed dose of Filgrastim where dose limiting toxicity defined as any grade 4 non-hematologic toxicity observed within 28 days from Day 0 (day of transplant).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Failure</measure>
    <time_frame>Baseline till disease progression/death, up to 1 year.</time_frame>
    <description>Time to treatment failure defined as either disease recurrence or death, measured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Engraftment Versus Graft Failure)</measure>
    <time_frame>100 Days post engraftment</time_frame>
    <description>Engraftment: first day of three (3) consecutive days that Absolute neutrophil count (ANC) exceeds 0.5 X 109/L. Subsequent chimerism studies must demonstrate the presence of donor derived cells. Graft Failure: failure to achieve an ANC &gt;0.5 X 109/L for 3 consecutive days within 28 days after transplantation or a decline of ANC &lt;0.5 x 109/L for three consecutive days after initial documented engraftment unless this is correlated with progression / recurrence of the underlying malignancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>AMD3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Busulfex™</other_name>
    <other_name>Myleran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic blood stem cell transplant</intervention_name>
    <description>Stem Cell Infusion (Bone marrow or PBPC)</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Bone Marrow Transplantation</other_name>
    <other_name>Blood Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG (Thymoglobulin)</intervention_name>
    <description>Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Antithymocyte globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients age &gt;/=18 to &lt;/= 65 years.

          2. Diagnosis of AML in first or greater remission, first or subsequent relapse, or
             primary induction failure; MDS with intermediate or high risk International Prognostic
             Scoring System (IPSS) score having failed to respond or recurred after chemotherapy;
             in remission or having active disease after treatment; AML arising from MDS; or CML
             which has failed to respond to imatinib or other tyrosine kinase inhibitor and has had
             &gt;5% blasts in the blood or bone marrow. Patients receiving second transplants after
             relapse are considered in the relapse group.

          3. White Blood Count (CBC) &lt;/= 20 * 10^9/l.

          4. Patients should have a histocompatible, related or unrelated volunteer donor
             available. A histocompatible donor is defined as HLA matched related donor or an
             unrelated donor matched for HLA- A, B, C, and DR antigens by high-resolution DNA
             techniques.

          5. Zubrod performance status 0 or 1, or Karnofsky performance status 90-100%.

          6. Left ventricular ejection fraction &gt;/= 45 %. No uncontrolled arrhythmias or
             uncontrolled symptomatic cardiac disease.

          7. No symptomatic pulmonary disease. Forced expiratory volume in 1 s (FEV1), forced vital
             capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) &gt;/= 50 % of expected,
             corrected for hemoglobin.

          8. Serum creatinine &lt;/=1.5 mg/dl.

          9. Serum glutamic pyruvic transaminase (SGPT) &lt;/= 200 IU/ml unless related to the
             malignancy.

         10. Total serum bilirubin &lt;/=1.5 mg/dl (unless Gilbert's syndrome) and alkaline
             phosphatase &lt;/=2.5 times laboratory standard upper limit of normal (ULN).

         11. Patient or patient's legal representative able to sign informed consent.

        Exclusion Criteria:

          1. History of HIV positive.

          2. Positive Beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization.

          3. Pleural/pericardial effusion or ascites estimated &gt;/= 1 liter.

          4. Uncontrolled infection, not responding to appropriate antimicrobial agents after seven
             days of therapy.

          5. History of acute hepatitis, chronic active hepatitis or cirrhosis.

          6. Patients with class 3 or 4 angina (New York Heart Association (NYHA) criteria).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Konopleva, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <results_first_submitted>June 13, 2014</results_first_submitted>
  <results_first_submitted_qc>June 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Stem Cell Transplantation</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Bone Marrow Cell Transplantation</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Allogeneic Hematopoietic Transplantation</keyword>
  <keyword>Advanced Myeloid Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Graft Versus Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>ATG</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex™</keyword>
  <keyword>Myleran®</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara™</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Plerixafor</keyword>
  <keyword>Antithymocyte globulin</keyword>
  <keyword>Thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period:</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Plerixafor + G-CSF</title>
          <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
Allogeneic blood stem cell transplant : Stem Cell Infusion (Bone marrow or PBPC)
Filgrastim : Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
Fludarabine : Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
Thymoglobulin (ATG) : Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Busulfan : Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
Plerixafor : Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plerixafor + G-CSF</title>
          <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
Allogeneic blood stem cell transplant : Stem Cell Infusion (Bone marrow or PBPC)
Filgrastim : Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
Fludarabine : Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
ATG (Thymoglobulin) : Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Busulfan : Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
Plerixafor : Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="25" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) Plerixafor</title>
        <description>MTD dose of Plerixafor in combination with a fixed dose of Filgrastim where dose limiting toxicity defined as any grade 4 non-hematologic toxicity observed within 28 days from Day 0 (day of transplant).</description>
        <time_frame>28 day cycle (Plerixafor Day -7 to Day -4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor + G-CSF</title>
            <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
Allogeneic blood stem cell transplant : Stem Cell Infusion (Bone marrow or PBPC)
Filgrastim : Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
Fludarabine : Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
ATG (Thymoglobulin) : Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Busulfan : Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
Plerixafor : Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) Plerixafor</title>
          <description>MTD dose of Plerixafor in combination with a fixed dose of Filgrastim where dose limiting toxicity defined as any grade 4 non-hematologic toxicity observed within 28 days from Day 0 (day of transplant).</description>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Failure</title>
        <description>Time to treatment failure defined as either disease recurrence or death, measured in months.</description>
        <time_frame>Baseline till disease progression/death, up to 1 year.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (Engraftment Versus Graft Failure)</title>
        <description>Engraftment: first day of three (3) consecutive days that Absolute neutrophil count (ANC) exceeds 0.5 X 109/L. Subsequent chimerism studies must demonstrate the presence of donor derived cells. Graft Failure: failure to achieve an ANC &gt;0.5 X 109/L for 3 consecutive days within 28 days after transplantation or a decline of ANC &lt;0.5 x 109/L for three consecutive days after initial documented engraftment unless this is correlated with progression / recurrence of the underlying malignancy.</description>
        <time_frame>100 Days post engraftment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The active treatment period defined as study entry through Stem Cell Transfusion Day +28, follow up defined as Transfusion Day +29 through Day +100. Overall study period 3 years and 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Plerixafor + G-CSF</title>
          <description>ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
Allogeneic blood stem cell transplant : Stem Cell Infusion (Bone marrow or PBPC)
Filgrastim : Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
Fludarabine : Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
ATG (Thymoglobulin) : Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Busulfan : Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
Plerixafor : Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Prolonged hospitalization/Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cyctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="49" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <description>Fever, chills</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marina Konopleva, MD, PhD / Associate Professor</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-794-1628</phone>
      <email>mkonople@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

